Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002355 · ClinicalTrials.gov registry record · NA
A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes
A NA study, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 60
- Enrollment target
NCT00002355 is a NA study that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 60 participants.
The verdict
NCT00002355, a NA study, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 60 participants
- Enrollment target
Study Summary
To determine a clinically safe and effective dose of intravitreally injected ISIS 2922 and to compare the safety and efficacy of immediate versus delayed treatment in AIDS patients with previously untreated, peripheral cytomegalovirus ( CMV ) retinitis.
Interventions
- DRUG Fomivirsen sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002355
The ClinicalTrials.gov registry entry for NCT00002355 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fomivirsen sodium is the first listed.
NCT00002355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002355 about?
NCT00002355 is a clinical study titled "A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes". To determine a clinically safe and effective dose of intravitreally injected ISIS 2922 and to compare the safety and efficacy of immediate versus delayed treatment in AIDS patients with previously untreated, peripheral cytomegalovirus ( CMV ) retinitis.
What is the current status of trial NCT00002355?
This trial is currently completed. It is a NA study. The enrollment target is 60 participants.
What interventions are being tested in trial NCT00002355?
The interventions under investigation include: Fomivirsen sodium (DRUG).
Who is sponsoring clinical trial NCT00002355?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.